|1.||Tanaka, Taisaku: 2 articles (10/2011 - 12/2008)|
|2.||Ogata, Atsuto: 2 articles (10/2011 - 12/2008)|
|3.||Maruoka, Hiroshi: 2 articles (10/2011 - 12/2008)|
|4.||Fukuda, Yoshiaki: 2 articles (10/2011 - 12/2008)|
|5.||Nagahira, Kazuhiro: 2 articles (10/2011 - 12/2008)|
|6.||Fujieda, Yusuke: 2 articles (10/2011 - 12/2008)|
|7.||Muto, Tsuyoshi: 2 articles (10/2011 - 12/2008)|
|8.||Terakawa, Maki: 2 articles (10/2011 - 12/2008)|
|9.||Tomimori, Yoshiaki: 2 articles (10/2011 - 12/2008)|
|10.||Igawa, Yoshiyuki: 1 article (01/2014)|
|1.||Atopic Dermatitis (Atopic Eczema)
10/01/2011 - "In the present study, effective dosages of SUN13834 for atopic dermatitis patients were predicted by pharmacokinetic/pharmacodynamic (PK/PD) analyses of SUN13834 in NC/Nga mice, which spontaneously develop atopic dermatitis-like skin lesions. "
12/28/2008 - "In conclusion, SUN13834 is thought to be useful as therapeutic agent for atopic dermatitis."
10/01/2011 - "A chymase inhibitor SUN13834 has been shown to improve skin condition in animal models for atopic dermatitis. "
01/01/2014 - "1. A novel oral chymase inhibitor, SUN13834, is under clinical development for the treatment of atopic dermatitis (AD). "
10/01/2011 - "Pharmacokinetic/pharmacodynamic analyses of chymase inhibitor SUN13834 in NC/Nga mice and prediction of effective dosage for atopic dermatitis patients."
10/01/2011 - "In late-phase reaction of biphasic dermatitis, SUN13834 was most effective when its plasma concentration was highest at the elicitation, and the minimum effective plasma concentration of unbound SUN13834 at the elicitation was calculated to be 0.13-0.2 ng/mL. Oral administration of SUN13834 improved dermatitis in NC/Nga mice at 15 mg/kg (twice a day; bid) and 30 mg/kg (once a day; qd), but not at 60 mg/kg (every other day; eod). "
10/01/2011 - "For the PK/PD analyses, we utilized the minimum effective plasma concentration of unbound SUN13834 in late-phase reaction of trinitrochlorobenzene (TNCB)-induced biphasic dermatitis in mice, based on the assumption that the minimum effective plasma concentrations are the same among the two animal models. "
12/28/2008 - "It has already been shown that chymase inhibitor SUN13834 improves dermatitis in NC/Nga mice that spontaneously develop dermatitis resembling atopic dermatitis. "
12/28/2008 - "In the present study, effect of chymase inhibitor SUN13834 on itch, the major feature of atopic dermatitis, was examined using a mouse dermatitis model induced by repeated topical application of 2,4-dinitrofluorobenzene (DNFB). "
|5.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|3.||Picryl Chloride (Trinitrochlorobenzene)